# Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

> **NCT00627354** · PHASE2 · COMPLETED · sponsor: **Groupe D'Etude des Tumeurs Uro-Genitales** · enrollment: 90 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** etoposide
- **DRUG:** mitoxantrone hydrochloride
- **DRUG:** prednisone
- **DRUG:** vinorelbine tartrate

## Key facts

- **NCT ID:** NCT00627354
- **Lead sponsor:** Groupe D'Etude des Tumeurs Uro-Genitales
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2011-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00627354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00627354, "Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00627354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*